University Of California San Francisco

Racial and ethnic disparities in BP control may be explained in part by differences in treatment intensification and missed follow-up visits, researchers reported in JAMA Cardiology.

Race did not significantly predict response to treatment outcomes among women with high-risk breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The addition of pembrolizumab to first-line chemotherapy conferred clinically meaningful benefit to patients with inoperable or metastatic triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

The addition of pembrolizumab to neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended EFS for patients with early triple-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

Among patients with HIV on antiretroviral therapy, AKI incidence fluctuated between 2005 and 2015 without significant temporal trends, according to a speaker at ASN Kidney Week.

Bispecific T-cell engagers have induced impressive response rates among patients with relapsed or refractory multiple myeloma enrolled in early clinical trials.

Among patients with fibrotic interstitial lung disease, low BMI and weight loss were independently associated with increased 1-year mortality, researchers reported in Chest.

John F. de Groot, MD, has been appointed chief of the neuro-oncology division at University of California, San Francisco.

The American Academy of Neurology has issued ethical guidance on Aduhelm that outlines important points for neurologists to communicate to patients eligible for the treatment.

Measurement of residual cancer burden served as both an accurate and consistent indicator of prognosis across breast cancer subtypes, according to an analysis of data from the randomized I-SPY2 trial published in JAMA Oncology.